A federal health advisory panel on Thursday narrowly recommended easing access to several peptide drugs that currently lack FDA approval. The decision follows a contentious debate regarding the substances, which have gained significant popularity among wellness influencers and celebrities.
Government scientists have cautioned against the move, noting that these chemicals have not undergone the rigorous safety and efficacy testing required for standard FDA approval. The panel’s recommendation marks a significant development in a politically charged controversy surrounding the use of compounded peptides, highlighting a growing tension between public demand for these treatments and established regulatory oversight.
In-depth summary · AI, neutral